CA2904447A1 — Therapy for complications of diabetes

USPTO Abstract

A selective ET A receptor antagonist for use in a method for enhancing glycemic control and/or insulin sensitivity in a human subject having diabetic nephropathy and/or metabolic syndrome is disclosed. A selective ET A receptor antagonist for use in treating a complex of comorbidities in an elderly diabetic human subject, wherein the selective ET A receptor antagonist is for administration in combination or as adjunctive therapy with (a) at least one additional agent that is (i) other than a selective ET A receptor antagonist and (ii) effective in treatment of diabetes and/or at least one of said comorbidities other than hypertension, and optionally (b) at least one antihypertensive other than a selective ET A receptor antagonist is disclosed. Further, a therapeutic combination comprising a selective ET A receptor antagonist and at least one antidiabetic, anti-obesity or antidyslipidemic agent other than a selective ET A receptor antagonist is disclosed.